Related references
Note: Only part of the references are listed.FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2020)
CD123 as a Therapeutic Target Against Malignant Stem Cells
Mayumi Sugita et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm
Narittee Sukswai et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor et al.
BLOOD (2019)
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
Katsuhiro Togami et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Hitting the bullseye with a nonlethal payload: resistance in CD123-positive malignancies
Lukasz P. Gondek
JOURNAL OF CLINICAL INVESTIGATION (2019)
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Hannah C. Beird et al.
BLOOD CANCER JOURNAL (2019)
Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis
Gwang Hun Jeong et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia
Nicole M. Cruz et al.
LEUKEMIA & LYMPHOMA (2018)
Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm
Guru Subramanian Guru Murthy et al.
LEUKEMIA RESEARCH (2018)
Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm
Mounzer E. Agha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Detection of Minimal Bone Marrow involvement of Blastic Plasmacytoid Dendritic Cell Neoplastic Cells - CD303 immunostaining as a diagnostic tool
Rintaro Ohe et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Joan Montero et al.
CANCER DISCOVERY (2017)
Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
Naveen Pemmaraju
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches
Livio Pagano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
Tomohiro Aoki et al.
BLOOD (2015)
Single-Cell Mass Cytometry Reveals Intracellular Survival/Proliferative Signaling in FLT3-ITD-Mutated AML Stem/Progenitor Cells
Lina Han et al.
CYTOMETRY PART A (2015)
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile
Lourdes Martin-Martin et al.
ONCOTARGET (2015)
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
Fanny Angelot-Delettre et al.
HAEMATOLOGICA (2015)
Targeted diphtheria toxin to treat BPDCN
David J. FitzGerald
BLOOD (2014)
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Arthur E. Frankel et al.
BLOOD (2014)
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
Olga Frolova et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Ugo Testa et al.
BIOMARKER RESEARCH (2014)
TET2 Mutations, Myelodysplastic Features, and A Distinct Immunoprofile Characterize Blastic Plasmacytoid Dendritic Cell Neoplasm in the Bone Marrow
Khaled Alayed et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
Mohamed A. Kharfan-Dabaja et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Damien Roos-Weil et al.
BLOOD (2013)
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
Livio Pagano et al.
HAEMATOLOGICA (2013)
Molecular Profiling Of Blastic Plasmacytoid Dendritic CELL Neoplasm Reveals A Unique Pattern and Suggests Selective Sensitivity To NF-KB Pathway Inhibition
Pier Paolo Piccaluga et al.
BLOOD (2013)
Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance
Justin Taylor et al.
BLOOD (2013)
Blastic Plasmacytoid Dendritic Cell Neoplasm: Cytopathologic Findings
Gang Zheng et al.
ACTA CYTOLOGICA (2012)
TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm
Fabrice Jardin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
David J. FitzGerald et al.
CANCER RESEARCH (2011)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2011)
Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
S. Dalle et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
Arthur Frankel et al.
LEUKEMIA & LYMPHOMA (2008)
A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma
T Maeda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
RL Alexander et al.
LEUKEMIA RESEARCH (2001)
Identification of a leukemic counterpart of the plasmacytoid dendritic cells
L Chaperot et al.
BLOOD (2001)
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
E Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells
M Feuring-Buske et al.
EXPERIMENTAL HEMATOLOGY (2000)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor
AE Frankel et al.
PROTEIN ENGINEERING (2000)
In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein
RL Alexander et al.
BIOCONJUGATE CHEMISTRY (2000)
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
AE Frankel et al.
LEUKEMIA (2000)
Share Paper
